Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
MM-099: Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results From the CC-92480-MM-002 Trial
Irwindeep Sandhu, Paul G. Richardson, Albert Oriol, Darrell White, Richard Leblanc, Noopur Raje, Enrique M. Ocio, Aurore Perrot, Thierry Façon, Cesar Rodriguez, Ralph Wäsch, Meletios A Dimopoulos, Tracy T. Chow, Allison Gaudy, Jing Gong, Zehua Zhou, Tiziana Civardi, Joseph T. Hadala, Yue Zhu, Jessica Katz, Marc S. Raab (2025). MM-099: Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results From the CC-92480-MM-002 Trial. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)02558-3.
Article21 days agoDaratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS
Paula Rodríguez‐Otero, Peter M. Voorhees, Mario Boccadoro, Jacob P. Laubach, Hermann Einsele, Douglas W. Sborov, Meletios A Dimopoulos, Annemiek Broijl, Roberto Mina, Andrew Spencer, Fredrik Schjesvold, Rebecca Silbermann, Francesca Gay, Luciano J. Costa, Aurore Perrot, Yanfang Liu, Jianping Wang, Anna Sitthi-Amorn, Robin Carson, Annelore Cortoos, Saad Z. Usmani, Paul G. Richardson, Philippe Moreau, Pieter Sonneveld, Jonathan L. Kaufman (2025). Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS. , 25(10), DOI: https://doi.org/10.1016/j.clml.2025.04.007.
Article21 days agoPOSTER: MM-099 Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results From the CC-92480-MM-002 Trial
Irwindeep Sandhu, Paul G. Richardson, Albert Oriol, Darrell White, Richard Leblanc, Noopur Raje, Enrique M. Ocio, Aurore Perrot, Thierry Façon, Cesar Rodriguez, Ralph Wäsch, Meletios A Dimopoulos, Tracy T. Chow, Allison Gaudy, Jing Gong, Zehua Zhou, Tiziana Civardi, Joseph T. Hadala, Yue Zhu, Jessica Katz, Marc S. Raab (2025). POSTER: MM-099 Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results From the CC-92480-MM-002 Trial. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)01219-4.
Article21 days agoSubcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study
Nizar J. Bahlis, Jeffrey A. Zonder, Lionel Karlin, Torben Plesner, Laura París, Tomasz Wróbel, Vânia Hungria, Britta Besemer, Edvan Crusoé, Trine Silkjær, Aurore Perrot, Philippe Moreau, Ka Lung Wu, Sosana Delimpasi, Meletios A Dimopoulos, Mark‐David Levin, Silvia Mangiacavalli, Ivo Nnane, Yu Jin Kim, Maria Krevvata, Linlin Sha, Susan Wróblewski, Alba Tuozzo, Robin Carson, Thierry Facon (2025). Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study. , 66(14), DOI: https://doi.org/10.1080/10428194.2025.2561117.
Article21 days agoIsatuximab for the treatment of multiple myeloma: current clinical advances and future directions
Paul G. Richardson, Elisabeth K. O’Donnell, Peter O’Gorman, Lisa Leypoldt, Jacob P. Laubach, Francesca Gay, Xavier Leleu, Thierry Façon, Philippe Moreau, Meletios A Dimopoulos, Hartmut Goldschmidt, K. Elias, Michèle Cavo, Katja Weisel, Jesús G. Berdeja, Robert Z. Orlowski, Meral Beksaç, Aurore Perrot, Joseph Mıkhael, T. John Martin (2025). Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions. , 34(7-8), DOI: https://doi.org/10.1080/13543784.2025.2532446.
Article21 days ago